Mode
Text Size
Log in / Sign up
Phase 2 N=33 Randomized Triple-blind Treatment

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction · Flank Pain

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Spontaneous Stone Passage Using Fisher's Exact Test — 8; 5 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Mirabegron (Drug); Placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Baylor College of Medicine
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Spontaneous Stone Passage Using Fisher's Exact Test
8; 5
SECONDARY
Comparison of Pain Levels Between Treatment Groups Using the Wong-Baker Pain Rating Scale
0.21; 0.19

Summary

The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.

Eligibility Criteria

Inclusion Criteria

  • Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter
  • Serum creatinine within normal range
  • Ability to tolerate oral fluids and oral pain medication
  • Able to make informed medical decisions regarding consent
  • Willingness to follow-up in the Urology Clinic in approximately 30 day
  • Willing to undergo ureteroscopic extraction should the stone not pass in this time period

Exclusion Criteria

  • Adults unable to consent
  • Age less than 18
  • Multiple stones
  • Solitary kidney
  • Horseshoe kidney
  • On immunosuppressant therapy
  • On digoxin
  • Uncontrolled hypertension (Systolic blood pressure > 170, diastolic blood pressure > 110)
  • History of ureteral surgery or previous endoscopic procedure
  • Allergy to mirabegron
  • Current calcium antagonist or corticosteroid or tamsulosin usage
  • Patients already taking a beta-adrenergic agonist medication
  • Renal insufficiency [Glomerular Filtration Rate (GFR) less than 60]
  • Patients with Childs B and C liver failure
  • Signs of infection i. Temperature greater than 38 degrees Celsius ii. Urinalysis with any of the following positive:
  • Positive nitrites
  • White blood cell count greater than 15/hpf (high powered field)
  • Positive urine culture [defined as a single isolated bacterial species population of greater than 100,000 Colony Forming Units (CFU)]
  • Patients with chronic pain already undergoing treatment with narcotic medications
  • Pregnant women and nursing mothers
  • Prisoners
  • No working phone number
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02744430). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search